Accepted for Publication: April 22, 2019.
Corresponding Author: Nicholas Lintzeris, MBBS, PhD, Drug and Alcohol Services, South East Sydney Local Health District, 591 S Dowling St, Surry Hills, New South Wales, Australia 2010 (nicholas.lintzeris@health.nsw.gov.au).
Published Online: July 15, 2019. doi:10.1001/jamainternmed.2019.1993
Author Contributions: Drs Lintzeris and Mills had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Lintzeris, Dunlop, Copeland, McGregor, Bruno, Phung, Montebello, Hall, Jefferies, Shanahan, Allsop.
Acquisition, analysis, or interpretation of data: Lintzeris, Bhardwaj, Mills, Copeland, McGregor, Bruno, Gugusheff, Phung, Montebello, Chan, Kirby, Jefferies, Luksza, Shanahan, Kevin, Allsop.
Drafting of the manuscript: Lintzeris, Mills, Dunlop, Phung, Montebello, Kirby, Jefferies, Kevin, Allsop.
Critical revision of the manuscript for important intellectual content: Lintzeris, Bhardwaj, Mills, Dunlop, Copeland, McGregor, Bruno, Gugusheff, Phung, Montebello, Chan, Kirby, Hall, Jefferies, Luksza, Shanahan, Kevin.
Statistical analysis: Lintzeris, Bhardwaj, Mills, Bruno, Phung, Kirby.
Obtained funding: Lintzeris, Dunlop, Copeland, McGregor, Phung, Montebello, Shanahan, Allsop.
Administrative, technical, or material support: Lintzeris, Bhardwaj, Mills, Dunlop, McGregor, Bruno, Gugusheff, Phung, Montebello, Chan, Hall, Jefferies, Luksza, Shanahan, Allsop.
Supervision: Lintzeris, Copeland, Phung, Allsop.
Conflict of Interest Disclosures: Dr Lintzeris reported receiving grants from National Health and Medical Research Council of Australia during the conduct of the study; grants from Camurus, personal fees from Indivior and Mundipharma outside the submitted work; and being the Clinical Director of the Lambert Initiative in Cannabinoid Therapeutics at University of Sydney from 2015-2017, involved in a number of studies of medical cannabis, unrelated to this study. Dr McGregor reported receiving grants from National Health and Medical Research Council of Australia and from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study; having patents to WO2018107216A1, WO2017004674A1, and WO2011038451A1 issued and licensed; and having patents to AU2017904438, AU2017904072, and AU2018901971 pending. No other disclosures were reported.
Funding/Support: The study was an investigator-led trial with the University of Sydney as the study sponsor. National Health and Medical Research Council project grant 1088902 supported research costs, health services were predominantly funded by the participating New South Wales health services, and study medications were provided free by GW Pharmaceuticals.
Role of the Funder/Sponsor: The sponsor and funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Group Information: The Agonist Replacement for Cannabis Dependence (ARCD) study group members are Raelene Dojcinovic, Betty Jago, Lynsey McKendrick, Consuelo Rivas, Ricardo Schwanz, Abigail Yang, and Zachary Zavareh, all from South Eastern Sydney Local Health District; Susan Hazelwood, Josephine Hindson, Melissa Jackson, Julian Keats, Craig Sadler, and Anthony Winmill, all from Hunter New England Local Health District; Angelo Barbaro, Kerin Black, Pip Bowden, Jonathon Coreas, Tim Ho, Shyam Nagubandi, Mahsa Shahidi, Catherine Silsbury, Lisa Snell, and Matthew Wijanto, all from Western Sydney Local Health District.
Data Sharing Statement: See Supplement 3.
Additional Contributions: The Agonist Replacement for Cannabis Dependence (ARCD) study group members all contributed by participating in data collection and the delivery of study interventions. New South Wales Health Pathology Royal Prince Alfred Hospital assisted with the urinalysis for this study.
1.UN Office on Drugs and Crime. World Drug Report 2013. Vienna, Austria: UN Office on Drugs and Crime; 2013.
2.UN Office on Drugs and Crime. World Drug Report 2015. Vienna, Austria: UN Office on Drugs and Crime; 2015.
3.Australian Institute of Health and Welfare. 2016 National Drug Strategy Household Survey: Preliminary Findings. Canberra, Australia: Australian Institute of Health and Welfare; 2017.
5.World Health Organization. The Health and Social Effects of Nonmedical Cannabis Use. Geneva, Switzerland: World Health Organization; 2016.
6.Roffman
RA, Stephens
RS.
Cannabis Dependence: Its Nature, Consequences, and Treatment. Cambridge, UK: Cambridge University Press; 2006. doi:
10.1017/CBO9780511544248 8.Johnston
J, Lintzeris
N, McGregor
I, Allsop
DJ, Helliwell
D, Winstock
A. A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal: paper 220.
Drug Alcohol Rev. 2013;32:43.
Google Scholar 18.Bhardwaj
AK, Allsop
DJ, Copeland
J,
et al; Agonist Replacement for Cannabis Dependence (ARCD) study group. Randomised controlled trial (RCT) of cannabinoid replacement therapy (nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
BMC Psychiatry. 2018;18(1):140. doi:
10.1186/s12888-018-1682-2PubMedGoogle ScholarCrossref 19.World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). 2nd ed. Geneva, Switzerland: World Health Organization; 2005.
20.Copeland
J. Marijuana Brief Intervention: An SBIRT Approach. Center City, MN: Hazelden Publishing; 2017.
21.Sobell
LC, Sobell
MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds.
Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press Inc; 1992:41-72. doi:
10.1007/978-1-4612-0357-5_3 25.Larance
B, Bruno
R, Lintzeris
N,
et al. Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: the Opioid-Related Behaviours In Treatment (ORBIT) scale.
Drug Alcohol Depend. 2016;159:42-52. doi:
10.1016/j.drugalcdep.2015.11.026PubMedGoogle ScholarCrossref 33.Benjamini
Y, Hochberg
Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing.
J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
Google Scholar 35.R: a language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2016.
38.Therneau
TM, Grambsch
PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer Science & Business Media; 2013.
40.Teruya
C, Schwartz
RP, Mitchell
SG,
et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the Starting Treatment With Agonist Replacement Therapies (START) Study.
J Psychoactive Drugs. 2014;46(5):412-426. doi:
10.1080/02791072.2014.921743PubMedGoogle ScholarCrossref 41.Morgan
CJ, Freeman
TP, Schafer
GL, Curran
HV. Cannabidiol attenuates the appetitive effects of Δ 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Neuropsychopharmacology. 2010;35(9):1879-1885. doi:
10.1038/npp.2010.58PubMedGoogle ScholarCrossref